poisar

Stock

Adial Pharmaceuticals, Inc ADIL

$2.54-5.76%

Overview

ADIL market data

Price History

ADIL price chart

Valuation & Profitability

Alpha Vantage
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$4.89
Diluted earnings per share over the trailing twelve months.
Beta
1.27
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
0.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.31 – $18.90
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
$25.00
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Alpha Vantage OVERVIEW · market cap $4.6M · P/B 1.23.

Company news

8 captured
Adial Pharmaceuticals Form 13G Shows Coastlands Capital Partners Discloses 9.98% Passive Stake In Co. As Of June 17Benzinga · Jun 24, 2026, 2:45 PM
LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6Benzinga · Jun 15, 2026, 5:25 PM
Adial Pharmaceuticals shares are trading higher after the company announced it will acquire Azora Therapeutics in an all-stock deal. Also, the company has entered a private placement with potential gross proceeds of up to $64 million.Benzinga · Jun 11, 2026, 4:49 PM
8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)SEC EDGAR · Jun 11, 2026, 4:43 PM
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million FinancingBenzinga · Jun 11, 2026, 4:15 PM
Adial Pharmaceuticals Acquires Azora Therapeutics In All-Stock Transaction, Enters Concurrent Private Placement To Raise Up To $64MBenzinga · Jun 11, 2026, 3:51 PM
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightGlobenewswire Inc · Jun 8, 2026, 5:15 PM
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) EstimateBenzinga · May 8, 2026, 10:19 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock